In December 2025, the World Health Organisation (WHO) issued its first guidance on using Glucagon-Like Peptide 1 (GLP 1) therapies for treating obesity 1. The GLP-1 medications covered include liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro / Zepbound in the US). Obesity is a complex chronic disease and a major driver of non-communicable diseases, including… Read more »
What is the difference between sugar and added sugar? For those in the food and nutrition world, added sugar might be something we hear about every day. Global dietary recommendations continue to recommend reducing added sugar intake, legislation taxing added sugar content of foods or beverages is increasingly common, and the update to the nutrition… Read more »
Sign up for monthly updates featuring our latest expert insights, upcoming webinars, and much more.
Subscribe
